Open AccessPatient-Centered Home Cancer Screening Attitudes During COVID-19 Pandemic
Author(s) -
Christelle El Khoury,
Elizabeth K. Haro,
Martha Alves,
Marie Claire O'Dwyer,
Kate Meixner,
Laura Crespo Albiac,
Juaicoll Capizzano,
Manasi Ramakrishnan,
Cullen Salada,
Sherri Sheinfeld Gorin,
Masahito Jimbo,
Ananda Sen,
Diane M. Harper
Publication year - 2021
Publication title -
journal of patient-centered research and reviews
Language(s) - English
Resource type - Journals
eISSN - 2330-0698
pISSN - 2330-068X
DOI - 10.17294/2330-0698.1835
Subject(s) - medicine , cervical cancer , cancer screening , cancer , pandemic , colorectal cancer , family medicine , gynecology , obstetrics , covid-19 , disease , infectious disease (medical specialty)
The COVID-19 pandemic disrupted health care delivery of cancer screenings. The primary aim of our work was to evaluate the degree to which populations were accepting of home-based screenings for colorectal cancer (CRC) and cervical cancer (ie, primary human papillomavirus [HPV] testing). Three groups of adults having distinct health burdens that may affect acceptance of home-based cancer screening were identified through outpatient electronic medical records: those having survived a COVID-19 hospitalization; those having been positive for a non-COVID-19 respiratory illness; or those having type 2 diabetes. A total of 132 respondents (58% female) completed an online survey with hypothetical cases about their acceptance of home-based CRC or cervical cancer screening. Among women respondents, urine and vaginal screening for primary HPV testing was acceptable to 64% and 59%, respectively. Among both men and women, at-home CRC screening with fecal immunochemical test or Cologuard ® was acceptable to 60% of the respondents. When adjusting for education, women with a positive attitude toward home-based urine and vaginal screening were 49 times and 23 times more likely, respectively, to have a positive attitude toward CRC screening. These findings indicate that home-based cancer screens for CRC and primary HPV testing are acceptable to men and women and may allow for greater compliance with screening in the future.